Sarcoidosis and MIF gene polymorphism: A case-control study in an Irish population

European Respiratory Journal

Volumn 29, Issue 2, 2007, Pages 325-329

  Plant, B J ^a   Ghani, S ^a   O'Mahony, M J ^a   Morgan, L ^b   O'Connor, C M ^a   Morgan, K ^b   Baugh, J A ^a   Donnelly, S C ^a,c  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Macrophage migration inhibitory factor; Polymorphism; Sarcoidosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CALCIUM; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA GLUTAMYLTRANSFERASE; GENOMIC DNA; MIGRATION INHIBITION FACTOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLELE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ERYTHEMA NODOSUM; ERYTHROCYTE SEDIMENTATION RATE; FAMILY HISTORY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE FREQUENCY; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IRELAND; LUNG FUNCTION TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; SARCOIDOSIS; SCORING SYSTEM; THORAX RADIOGRAPHY;

ADULT; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HUMANS; IRELAND; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICROSATELLITE REPEATS; POLYMORPHISM, GENETIC; SARCOIDOSIS; SEQUENCE ANALYSIS, DNA;

EID: 33846913903     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00129905     Document Type: Article

References (31)

1. Costabel U. Sarcoidosis: clinical update. Eur Respir J 2001; 18: Suppl. 32, 56S-68S.
2. Statement on sarcoidosis, joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-755.
3. Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001; 164:2085-2091.
4. Rybicki BA, Kirkey KL, Major M, et al. Familial risk ratio of sarcoidosis in African-American sibs and parents. Am J Epidemiol 2001; 153: 188-193.
5. Brennan NJ, Crean P, Long JP, Fitzgerald MX. High prevalence of familial sarcoidosis in an Irish population. Thorax 1984; 39: 14-18.
6. Donnelly SC, Bucala R. Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol Med Today 1997; 3:502-507.
7. Bernhagen J, Bacher M, Calandra T, et al. An essential role for macrophage migration inhibitory factor in tuberculin delayed-type hypersensitivity reaction. J Exp Med 1996; 183: 277-282.
8. Donnelly SC, Haslett C, Reid PT, et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 1997; 3; 320-323.
9. Campbell PB, Kataria YP, Tolson TA. In vitro production of inhibitors of monocyte locomotion by the granuloma of sarcoidosis. Am Rev Respir Dis 1984; 130: 417-423.
10. Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6: 164-170.
11. Bacher M, Metz CN, Calandra T, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996; 93:7849-7854.
12. Rossi AG, Haslett C, Hirani N, et al. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest 1998; 101: 2869-2874.
13. de Jong YP, Abadia-Molina AC, Satoskar AR, et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001; 2: 1061-1066.
14. Baugh JA, Chitnis S, Donnelly SC, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002; 3:170-176.
15. Moller DR. Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 24-31.
16. Kunkel SL, Lukacs NW, Strieter RM, Chensue SW. Th1 and Th2 responses regulate experimental lung granuloma development. Sarcoidosis Vasc Diffuse Lung Dis 1996; 13: 120-128.
17. Costabel U. CD4/CD8 ratios in bronchoalveolar lavage fluid: of value for diagnosing sarcoidosis? Eur Respir J 1997; 10:2699-2700.
18. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J 1961; 5261: 1165-1172.
19. Hillerdal G, Nou E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis 1984; 130: 29-32.
20. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659-664.
21. Standardization of Spirometry. 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
22. Drent M, Wimsberger RM, de Vries J, van Dieijen-Visser MP, Wouters, EF, Schols AM. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999; 13: 718-722.
23. Mizue Y, Ghani S, Leng L, et al. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci USA 2005; 102: 14410-14415.
24. Plant BJ, Gallagher CG, Bucala R, et al. Cystic fibrosis, disease severity, and a macrophage migration inhibitory factor polymorphism. Am J Respir Crit Care Med 2005; 172: 1412-1415.
25. Donn RP, Shelley E, Ollier WE, Thomson W, British Paediatric Rheumatology Study Group, A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001; 44: 1782-1785.
26. Amoli MM, Donn RP, Thomson W, et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheumatol 2002; 29: 1671-1673.
27. Rybicki BA, Maliarik MJ, Poisson LM, Iannuzzi MC. Sarcoidosis and granuloma genes: a family-based study in African-Americans. Eur Respir J 2004; 24: 251-257.
28. Pietinalho A, Furuya K, Yamaguchi E, Kawakami Y, Selroos O. The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. Eur Respir J 1999; 13: 723-726.
29. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-1889.
30. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 70-74.
31. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003; 361: 598-604.